文献速递主动脉疾病

Anaconda支架开窗腔内主动脉修复术后的性别结局

Sex-Based Outcomes Following Fenestrated Endovascular Aortic Repair With the Anaconda Stent Graft.
PubMed 文献 · J Endovasc Ther · 2026-07-15

女性与男性在总死亡率、动脉瘤相关死亡率、技术成功、围术期并发症、内脏血管通畅率及再干预率方面均无显著差异,提示FEVAR在女性中可行且安全。

要点

  • 女性FEVAR术后中期结局与男性相当,支持该术式在女性中可行。
  • 内脏血管通畅率两组均极佳,再干预率相似(13.6% vs 14.6%,P=1.000)。

核心结论

  • 女性使用Anaconda支架行FEVAR的中期结局与男性相当,支持FEVAR在女性中的可行性。

主要发现

  • 再干预率女性13.6% vs 男性14.6%(P=1.000),内脏血管通畅率两组均极佳。

临床怎么用

  • 对于解剖条件合适的女性腹主动脉瘤患者,FEVAR是可考虑的安全可行选项。
  • 需关注女性永久性截瘫发生率(4.2% vs 0%)等个体化风险,并开展性别特异性策略研究。

局限性

  • 单中心回顾性设计,女性样本量有限(24例),可能影响统计效能。
  • 随访时间中位24个月,长期结局尚未明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Although women are less frequently affected by abdominal aortic aneurysms (AAAs), they experience significantly worse outcomes following endovascular aneurysm repair (EVAR). The fenestrated Anaconda endograft was developed to address complex aortic anatomy and may mitigate sex-based disparities in outcomes. This study evaluates sex-specific results following fenestrated EVAR (FEVAR) with the Anaconda device. METHODS: A retrospective single-centre cohort study was conducted including patients who underwent elective FEVAR using the Anaconda stent graft between 2013 and 2023. Primary endpoints were overall survival and freedom from aneurysm-related mortality. Secondary endpoints included technical success, procedure-related complications, graft patency, endoleak occurrence, and reintervention rates. RESULTS: One hundred six patients (24 females and 82 males) with a median follow-up of 24 months were analysed. Female patients had lower overall mortality without statistical significance (16.7% vs 25.9%, P = .311). There was no significant difference in freedom from aneurysm-related mortality between female and male patients (4.3% vs 0%, respectively; P = .511). Technical success was slightly higher in females (95.8% vs 91.4%, P = .700), while perioperative complication rates were comparable between sexes. Myocardial infarction occurred in 0% of female patients versus 1.2% of males (P = 1.000), stroke: 0% versus 0% (P = NA), and permanent paraplegia: 4.2% versus 0% (P = .511). Renal failure was absent in 82.6% of females versus 78.0% of males, mesenteric ischaemia occurred in 0% of females versus 1.2% of males (P = 1.000), and distal embolization in 4.2% versus 2.4%, respectively (P = 1.000). Mid-term follow-up showed excellent visceral vessel patency in both groups. Left renal artery patency was 100% in females versus 97.5% in males (P = 1.000); right renal artery patency was 100% versus 98.75%, respectively (P = 1.000); superior mesenteric artery patency was 100% in both groups (P = 1.000); and celiac trunk patency was 100% in females versus 98.3% in males (P = 1.000). The reintervention rates were similar between both groups (13.6% female vs 14.6% male, P = 1.000). CONCLUSIONS: This study demonstrates that female patients undergoing FEVAR with the Anaconda stent graft achieved comparable mid-term outcomes to male patients. These results support the feasibility of FEVAR in women and highlight the need for sex-specific strategies to further improve outcomes.Clinical ImpactThis study demonstrates that female patients undergoing fenestrated endovascular aortic repair (FEVAR) with the Anaconda stent graft can achieve outcomes comparable to those of male patients, despite known anatomical challenges. Although the number of female patients was limited, these findings suggest that FEVAR is a feasible and safe treatment option for appropriately selected women. Given the underrepresentation of female patients in complex endovascular aortic repair, these results contribute to a better understanding of sex-specific outcomes and may encourage clinicians to consider FEVAR more frequently in women, as well as to pursue continued research focusing on sex-specific differences and long-term outcomes.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Passos L, Zielasek C, Celik M, et al. Sex-Based Outcomes Following Fenestrated Endovascular Aortic Repair With the Anaconda Stent Graft. J Endovasc Ther. 2026. PMID: 42458753. doi:10.1177/15266028261463154

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。